These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 2480846)

  • 21. Comparison of the cytotoxic effects of the high- and low-molecular-weight anticancer agents on multidrug-resistant Chinese hamster ovary cells in vitro.
    Miyamoto Y; Oda T; Maeda H
    Cancer Res; 1990 Mar; 50(5):1571-5. PubMed ID: 2137371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in the microvascular architecture of colorectal liver metastases following the administration of SMANCS/lipiodol.
    Kuruppu D; Christophi C; Maeda H; O'Brien PE
    J Surg Res; 2002 Mar; 103(1):47-54. PubMed ID: 11855917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor-targeted chemotherapy with SMANCS in lipiodol for renal cell carcinoma: longer survival with larger size tumors.
    Tsuchiya K; Uchida T; Kobayashi M; Maeda H; Konno T; Yamanaka H
    Urology; 2000 Apr; 55(4):495-500. PubMed ID: 10736490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Recent advances in research on SMANCS].
    Maeda H
    Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():1-9. PubMed ID: 9512680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Antitumor effects of a new antitumor agent, zinostatin stimalamer (YM881)--effects on experimental tumors in vitro and in vivo].
    Numasaki Y; Takahashi K; Masuda E; Nohara C; Maeda H
    Gan To Kagaku Ryoho; 1991 Oct; 18(13):2289-94. PubMed ID: 1834021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Stability of high molecular weight anticancer agent SMANCS and its transfer from oil-phase to water-phase. Comparative study with neocarzinostatin].
    Hirayama S; Sato F; Oda T; Maeda H
    Jpn J Antibiot; 1986 Mar; 39(3):815-22. PubMed ID: 3016359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [SMANCS/lipiodol].
    Maeda H
    Gan To Kagaku Ryoho; 1994 May; 21(6):907-13. PubMed ID: 8185354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium.
    Maki S; Konno T; Maeda H
    Cancer; 1985 Aug; 56(4):751-7. PubMed ID: 3160453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Styrene maleic acid neocarzinostatin-transcatheter embolization for hepatocellular carcinoma--third report].
    Hasegawa I; Hirashima N
    Gan To Kagaku Ryoho; 2002 Feb; 29(2):253-9. PubMed ID: 11865632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image.
    Iwai K; Maeda H; Konno T
    Cancer Res; 1984 May; 44(5):2115-21. PubMed ID: 6324996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Experience with intraarterial infusion of styrene maleic acid neocarzinostatin (SMANCS)-lipiodol in pancreatic cancer.
    Yoshida H; Onda M; Tajiri T; Uchida E; Arima Y; Mamada Y; Yamamoto K; Kaneko M; Terada Y; Kumazaki T
    Hepatogastroenterology; 1999; 46(28):2612-5. PubMed ID: 10522050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiproliferative effect of YM881 (SMANCS) on glioma cells in vitro.
    Kuratsu J; Takaki S; Kochi M; Mihara Y; Ushio Y
    Anticancer Res; 1991; 11(6):1957-61. PubMed ID: 1837980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anticancer effects of arterial administration of the anticancer agent SMANCS with lipiodol on metastatic lymph nodes.
    Ohtsuka N; Konno T; Miyauchi Y; Maeda H
    Cancer; 1987 May; 59(9):1560-5. PubMed ID: 3030530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antitumor activities of oily suspended YM881 (SMANCS) against VX2 carcinoma].
    Kimura M; Konno T; Ohtsuka N; Mizumachi R; Oda T
    Gan To Kagaku Ryoho; 1989 Jun; 16(6):2183-8. PubMed ID: 2544148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Binding to and internalization by cultured cells of neocarzinostatin and enhancement of its actions by conjugation with lipophilic styrene-maleic acid copolymer.
    Oda T; Maeda H
    Cancer Res; 1987 Jun; 47(12):3206-11. PubMed ID: 2953411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor-targeted chemotherapy with lipid contrast medium and macromolecular anticancer drug (SMANCS) for renal cell carcinoma.
    Kobayashi M; Imai K; Sugihara S; Maeda H; Konno T; Yamanaka H
    Urology; 1991 Mar; 37(3):288-94. PubMed ID: 1848030
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prevention of hepatic metastases in rabbits by administration of an oily anticancer agent into the portal vein].
    Yamasaki K; Konno T; Miyauchi Y; Maeda H
    Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 1):1224-8. PubMed ID: 3034169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel dosage approach for evaluation of SMANCS [poly-(styrene-co-maleyl-half-n-butylate) - neocarzinostatin] in the treatment of primary hepatocellular carcinoma.
    Seymour LW; Olliff SP; Poole CJ; De Takats PG; Orme R; Ferry DR; Maeda H; Konno T; Kerr DJ
    Int J Oncol; 1998 Jun; 12(6):1217-23. PubMed ID: 9592177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Principle and therapeutic effect of lipophilic anticancer agent [SMANCS/lipiodol]: selective targeting with oily contrast medium].
    Maeda H
    Gan To Kagaku Ryoho; 1989 Oct; 16(10):3323-31. PubMed ID: 2552930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS.
    Maeda H; Sawa T; Konno T
    J Control Release; 2001 Jul; 74(1-3):47-61. PubMed ID: 11489482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.